BioPoly® Granted US Patent

October 15, 2019

FORT WAYNE, IN – BioPoly LLC has announced that another U.S. patent has been granted for its partial resurfacing implants. Where many of the other BioPoly® patents address the unique material, this patent family focuses on the innovative implant designs. With BioPoly’s recent approval from the FDA to begin an IDE Clinical study in the US for its BioPoly RS Partial Resurfacing Knee implant, this most recent patent, entitled “Partial joint resurfacing implant, instrumentation, and method”, adds to the Company’s intellectual property portfolio to provide the assurance that all aspects of the implants, material, and surgical technique are protected throughout the world.

The unique BioPoly® material behaves like a synthetic cartilage because of its patented combination of a lubricating molecule found in the knee and other joints along with an orthopaedic polymer (polyethylene based). The BioPoly® material is being used to replace damaged cartilage of a patient’s joint rather than to replace the entire joint, thus, allowing patients to quickly return to active, pain-free lifestyles. Patients in Europe have been receiving the implants since 2012.

About BioPoly, LLC

BioPoly LLC is an ISO 13485 certified orthopaedic implant manufacturer located in Fort Wayne, Indiana. The Company is developing, manufacturing and marketing products for use in sports medicine and orthopaedics. Additional medical applications of the BioPoly® technology in cardiovascular, spinal, and trauma markets are also being pursued.

Additional information about BioPoly LLC and its partial joint resurfacing technology can be found on the BioPoly website (

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button